^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study

Excerpt:
The median age was 65 years (range: 24-93); 87% of patients had Eastern Cooperative Oncology Group performance status 0-1, 56% of patients had KRAS, 7% had NRAS and 4% had BRAF mutations. The initial regorafenib dose was 160 mg/day in 57% of patients….Median OS was 7.7 months (95% confidence interval [CI]: 7.2-8.3), and median progression-free survival (PFS) was 2.9 months (95% CI: 2.8-3.0).
DOI:
10.1016/j.ejca.2019.09.015
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in Europe

Excerpt:
...Descriptive summary of demographics characteristics`Descriptive summary of Stage of disease`Descriptive summary of Eastern Cooperative Oncology Group (ECOG) performance status`Descriptive summary of Primary tumor status`Descriptive summary of Number of metastatic`Descriptive summary of Site of metastasis`Descriptive summary of K-RAS mutation status and N-RAS mutation status`Descriptive summary of Line of therapy (LOT) for regorafenib`Descriptive summary of Prior adjuvant treatment`Descriptive summary of Treatments prior to index date, overall and by LOT`Descriptive summary of Pre-existing comorbidities...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

maintenance therapy with regorafenib

Excerpt:
...•Male or female patients > 18 years •Histological or cytological documentation of adenocarcinoma of the colon or rectum •Genetic diagnosis of RAS(hot spot mutations KRAS codon 2-3-4 and NRAS at least codon 2-3) wild type tumor . ...
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.

Published date:
05/26/2022
Excerpt:
At data cut-off, median treatment duration and median follow-up were 4.6 mo. (range: 2.3; 10) and 13.4 mo. (range: 3.8; 18.0), respectively. One DLT (a grade 3 hypokalaemia related to grade 2 diarrhoea) occurred at DL 2. MTD was not reached at DL 3 (REGO 160 mg/day). The most common grade ≥3 TRAE per patient were grade 3 neutropenia (n = 1), grade 4 neutropenia (n = 1), grade 3 neuropathy (n = 2) and grade 3 diarrhoea (n = 7). Dose reductions/discontinuations due to grade ≥3 TRAE were necessary in 12/13 (92%) pts. The ORR was 62% (95% CI 32%-86%) and median PFS was 9.1 mo (range: 3.1; 15.4). Full-dose FOLFIRINOX plus full-dose REGO (160mg/day, days 4 to 10) can be administered safely. Due to the manageable toxicity profile and the promising efficacy observed in the dose-escalation stage...
Secondary therapy:
FOLFIRINOX
DOI:
10.1200/JCO.2022.40.16_suppl.3561
Trial ID: